215 related articles for article (PubMed ID: 36655340)
1. Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States.
Valentine WJ; Hoog M; Mody R; Belger M; Pollock R
Diabetes Obes Metab; 2023 May; 25(5):1292-1300. PubMed ID: 36655340
[TBL] [Abstract][Full Text] [Related]
2. Tirzepatide 10 and 15 mg vs semaglutide 2.0 mg: A long-term cost-effectiveness analysis in patients with type 2 diabetes in the United States.
Mody R; Valentine WJ; Hoog M; Sharland H; Belger M
J Manag Care Spec Pharm; 2024 Feb; 30(2):153-162. PubMed ID: 38308628
[TBL] [Abstract][Full Text] [Related]
3. Short-term cost-effectiveness analysis of tirzepatide for the treatment of type 2 diabetes in the United States.
Zhang X; McAdam Marx C
J Manag Care Spec Pharm; 2023 Mar; 29(3):276-284. PubMed ID: 36840958
[No Abstract] [Full Text] [Related]
4. Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting.
Martín V; Vidal J; Malkin SJP; Hallén N; Hunt B
Adv Ther; 2020 Oct; 37(10):4427-4445. PubMed ID: 32862365
[TBL] [Abstract][Full Text] [Related]
5. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK.
Johansen P; Chubb B; Hunt B; Malkin SJP; Sandberg A; Capehorn M
Adv Ther; 2020 May; 37(5):2427-2441. PubMed ID: 32306244
[TBL] [Abstract][Full Text] [Related]
7. Cost per Patient Achieving Treatment Targets and Number Needed to Treat with Tirzepatide Versus Semaglutide 1 mg in Patients with Type 2 Diabetes in the United States.
Mody RR; Meyer KL; Ward JM; O'Day KB
Diabetes Ther; 2023 Dec; 14(12):2045-2055. PubMed ID: 37770706
[TBL] [Abstract][Full Text] [Related]
8. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
Nauck MA; D'Alessio DA
Cardiovasc Diabetol; 2022 Sep; 21(1):169. PubMed ID: 36050763
[TBL] [Abstract][Full Text] [Related]
9. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
Malkin SJP; Russel-Szymczyk M; Psota M; Hlavinkova L; Hunt B
Adv Ther; 2019 Aug; 36(8):2034-2051. PubMed ID: 31168765
[TBL] [Abstract][Full Text] [Related]
10. Semaglutide versus tirzepatide for people with type 2 diabetes: cost of glycemic control in Austria, the Netherlands, Lithuania, and the United Arab Emirates.
Reitzel SB; Bøgelund M; Basse A; Barszczewska O; Ren H
Curr Med Res Opin; 2023 Aug; 39(8):1055-1060. PubMed ID: 37415503
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison.
Vadher K; Patel H; Mody R; Levine JA; Hoog M; Cheng AY; Pantalone KM; Sapin H
Diabetes Obes Metab; 2022 Sep; 24(9):1861-1868. PubMed ID: 35589616
[TBL] [Abstract][Full Text] [Related]
12. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands.
Hunt B; Malkin SJP; Moes RGJ; Huisman EL; Vandebrouck T; Wolffenbuttel BHR
BMJ Open Diabetes Res Care; 2019; 7(1):e000705. PubMed ID: 31641522
[TBL] [Abstract][Full Text] [Related]
13. The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.
Franch-Nadal J; Malkin SJP; Hunt B; Martín V; Gallego Estébanez M; Vidal J
Adv Ther; 2022 Jul; 39(7):3180-3198. PubMed ID: 35553372
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK.
Viljoen A; Hoxer CS; Johansen P; Malkin S; Hunt B; Bain SC
Diabetes Obes Metab; 2019 Mar; 21(3):611-621. PubMed ID: 30362224
[TBL] [Abstract][Full Text] [Related]
15. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K;
N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647
[TBL] [Abstract][Full Text] [Related]
16. Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.
Lingvay I; Cheng AY; Levine JA; Gomez-Valderas E; Allen SE; Ranta K; Torcello-Gómez A; Thieu VT
Diabetes Obes Metab; 2023 Apr; 25(4):965-974. PubMed ID: 36514843
[TBL] [Abstract][Full Text] [Related]
17. Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis.
Azuri J; Hammerman A; Aboalhasan E; Sluckis B; Arbel R
Diabetes Obes Metab; 2023 Apr; 25(4):961-964. PubMed ID: 36507900
[TBL] [Abstract][Full Text] [Related]
18. Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison.
Osumili B; Fan L; Paik JS; Pantalone KM; Ranta K; Sapin H; Tofé S
Diabetes Res Clin Pract; 2024 Jun; 212():111717. PubMed ID: 38777128
[TBL] [Abstract][Full Text] [Related]
19. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
Gorgojo-Martínez JJ; Malkin SJP; Martín V; Hallén N; Hunt B
J Med Econ; 2020 Feb; 23(2):193-203. PubMed ID: 31613199
[No Abstract] [Full Text] [Related]
20. The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal.
Malkin SJP; Carvalho D; Costa C; Conde V; Hunt B
Diabetol Metab Syndr; 2022 Feb; 14(1):32. PubMed ID: 35164855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
